News: International
25 November 2025
DLBS Brings Indonesia’s Biodiversity to the Global Pharmaceutical Stage at CPHI Frankfurt 2025
As global interest in herbal medicines continues to grow, only a limited number of products are developed with rigorous scientific methods and supported by strong clinical evidence. DLBS addresses this gap through the development of Integrative Modern Natural Medicines—therapeutics based on defined bioactive fractions with clear mechanisms of action and…
16 October 2025
30,000 Medicinal Plants, Only 20 Phytopharmaceuticals: Dexa Medica Strengthens Indonesia’s Role at the 16th WHO–IRCH Global Forum
Dexa Medica once again demonstrates its strong commitment as a national pharmaceutical company that plays a vital role in strengthening Indonesia’s pharmaceutical independence, particularly through the development of natural-based medicines. This commitment was reflected in its active contribution to the prestigious 16th Annual Meeting of the WHO–International Regulatory Cooperation for…
12 August 2025
Dexa Group Forms Strategic Alliance with AC Health to Expand Access to Quality and Affordable Generic Medicines in the Philippines
MANILA — AC Health has formed a strategic alliance with Glorious Dexa Mandaya Philippines, a subsidiary of the Indonesian pharmaceutical company Dexa Group, to enhance the availability of quality and affordable medicines for Filipinos. The partnership will focus on distributing Dexa Group’s affordable medicines and healthcare products, leveraging AC Health’s…
9 May 2023
STIMUNO Forte Boosts the Immune of Indonesian Contingent for the 2023 SEA Games in Cambodia
Dexa Group supports Indonesia in the 2023 SEA Games in Cambodia by providing the STIMUNO Forte immunomodulator. The product helps to boost Indonesian contingents' immunity to participate in a series of matches. This donation was given through the Embassy of the Republic of Indonesia in Phnom Penh & the Indonesian…
20 October 2022
Reinforcing Pharmaceutical Products Export Commitment to Europe, Dexa Group Signs MoU with Dutch and Polish Companies
Dexa Group, a pharmaceutical company with a high international standard in Indonesia, has reaffirmed its commitment to exporting its goods to Europe. Dexa Group inked a collaboration agreement with Allgen Pharmaceutical & Generic B.V from the Netherlands and Bioton S.A from Poland through its subsidiary Ferron Par Pharmaceuticals. Allgen Pharmaceutical…
18 March 2022
Dexa Group Attends the Inauguration of the ‘Pengabdian Dokter Indonesia’ Monument in Memory of Indonesian Doctors Who Served During the Pandemic
The Indonesian Doctors Association inaugurated the erection of a monument named "Pengabdian Dokter Indonesia" to remember the services of doctors who died to preserve the lives of Indonesians while dealing with COVID-19. Dexa Group took part in the establishment and inauguration of the monument, which took place on Thursday, March…
22 October 2021
Dexa Medica Wins Primaniyarta Award 2021 for OMAI Stimuno’s Marketing Achievements Abroad
PT Dexa Medica won the Primaniyarta 2021 award for the New Market Pioneer category. The Primaniyarta 2021 winners' awards were announced at the opening ceremony of the Trade Expo Indonesia Digital Edition (TEI DE), on Thursday, October 21, 2021. The President of the Republic of Indonesia, Mr. Joko Widodo (Jokowi)…
1 September 2021
Dexa Group Ramps Up Business in SE Asia by Launching Glorious Dexa Singapore Pte. Ltd.
Dexa Group, the leading pharmaceutical company from Indonesia, is ramping up its business in Southeast Asia with the launch of Glorious Dexa Singapore, Pte. Ltd. (GDS) based in Singapore. Dexa Group has exported medicines to various countries starting with Myanmar since 1993 and began exporting international standard medicines to Singapore…
2 August 2021
Regdanvimab Reduced The Risk of COVID-19-related Hospitalization or Death for Patients with Comorbidities
Regdanvimab (RegkironaTM) is recommended to treat confirmed COVID-19 in adult patients who do not require supplemental oxygen therapy and are at high risk of progressing to severe COVID-19. The recommended dosage of Regdanvimab is a single intravenous infusion of 40 mg/kg. Treatment should be initiated as soon as possible after…
4 June 2021
Dexa Medica Launches Konos: Double Attack Agains Cold and Cough
Dexa Medica, a leading multinational pharmaceutical company in Indonesia through its Nigerian distribution partner Orange Drugs Ltd launches a very effective and highly recommended cold and cough brand named Konos. Konos, aimed at providing relief from cold and cough disturbing and interrupting the daily lives and activities of Nigerians. At…
